A Ludwig Cancer Research study has developed a novel nanotechnology that triggers potent therapeutic anti-tumor immune responses and demonstrated its efficacy in mouse models of multiple cancers. Led by Co-director Ralph Weichselbaum, investigator Wenbin Lin and postdoctoral researcher Kaiting Yang at the Ludwig Center at Chicago, the study describes the synthesis, mechanism of action and preclinical assessment of the nanoparticle, which is loaded with a drug that activates a protein central to the efficient induction of anti-cancer immunity.

Since its first demonstration in 2004, the large-scale commercial production of graphene has proven difficult and costly (‘large scale’ usually defined as weights more than 200 mg or films larger than 200 cm2). For instance, at an estimated cost of $50 000 to $200 000 per ton for graphene powders and $45 000 to $100 000 per m2 of graphene film, industrial production methods and costs are restraining graphene utility.